Aktive Positionen von Greg Mann
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| NKARTA, INC. | Investor Relations Kontakt | 01.02.2020 | - |
| Public Communications Contact | 01.02.2020 | - |
Karriereverlauf von Greg Mann
Ehemalige bekannte Positionen von Greg Mann
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Abgenix, Inc.
 Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA. | Investor Relations Kontakt | - | 01.01.2006 |
| KITE PHARMA INC | Investor Relations Kontakt | 01.01.2016 | - |
| Public Communications Contact | - | - | |
| FIBROGEN, INC. | Investor Relations Kontakt | 01.03.2013 | - |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Investor Relations Contact | 4 |
| Public Communications Contact | 2 |
Sektoral
| Health Technology | 5 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| NKARTA, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Abgenix, Inc.
Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA. | Health Technology |
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
